PO.ET01.06 · 实验与分子治疗
Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
- 3166 3166 TKI adaptive resistance in HER2-driven non-small cell lung cancer at minimal residual disease stage can be targeted using cell surface-directed therapies Manale El Kharbili, Daniel Wilkinson, Lauren Giesy, Sharon R. Pine, Peter Fecci, Kyle Concannon
-
- 3168 3168 Fully human anti-HER-2 antibodies to HER-2 domains distinct from trastuzumab as antibody drug conjugates for tumor growth inhibition Ginette Serrero, Jianping Dong, Jun Hayashi
-
- 3170 3170 Combination of CDK4/6 inhibitory and anti-hypoxia miRNA-6883 lipid nanoparticles with ferroptosis inducers or MEK inhibitors in preclinical breast and colorectal cancer models Connor Purcell, Leiqing Zhang, Maryam Ghandali, Shulan Holmes-Farley, Audrey Yimin Su, Anais Sidonia, Ameen Raissi, Mackenzie Barrette, Emile Youssef, Theresa M. Raimondo, Wafik S. El-Deiry
- 3171 3171 Multitargeted kinase inhibitor LCI139 overcomes chemotherapy resistance in patient-derived non small cell lung cancer organoids by harnessing intrinsic and extrinsic apoptosis Anna Ivanina Foureau, Nadeem Wajih, Cody C. McHale, Hailey L. Dryden, Sara Muhiczukic, Dhananjaya Pal, Bharath Yada, David Foureau, Fei Guo, Raj Dhupar, Donald Durden, Konstantinos Votanopoulos, Shay Soker, Eleftherios Markis, Kathryn Mileham
- 3172 3172 XYD-8006: A novel ADAM9-targeting dual-payload ADC demonstrates superior preclinical efficacy in gastrointestinal and lung cancer models Weng Hang Ho, Pengfei Rong, Mengrui Zhao, Jun Li, Xidong Zhang, Hui Ding, Fangxing Ouyang
- 3173 3173 XYD-295 and XYD-338: Novel hydrophilic site specific linker platform enables next generation dual payload ADCs with enhanced efficacy and safety Weng Hang HO, Pengfei Rong, Mengrui Zhao, Jun Li, Xidong Zhang, Hui Ding, Fangxing Ouyang, Jun Wang, Jiangcheng Xu, Yang Liu, Jiawang Liu, Kyoungwoo Lee
-
- 3175 3175 Comparative efficacy of MUC1-C (XYA02) and MUC1-N (PankoMab, DS-3939a analog) antibody-drug conjugates in preclinical NSCLC Surender Kharbanda, Rehan Ahmad, Changchuin Mao, Sourav Choudhary, Brian Lawney, Govind Panchamoorthy, Ravi Jasuja
- 3176 3176 Tumor-selective regression through MUC16-guided DR5 (TNFRSF10B) clustering by the bispecific anti-MUC16×anti-DR5 antibody IMV-M™ Iosif M. Gershteyn, Viktor Goldmakher
-
- 3178 3178 Antifolate ADCs, a novel linker-drug platform for targeted therapy with a clear differentiating mechanism of action Ronald C. Elgersma, Renier C. Heijkants, Eline M. Loosveld, Noortje Veen, Chiel A. J. van der Horst, Iris van de Wetering, Arne J. Bramer, Erik Swiers, Tijl Huijbregts, Mike M. Ruth, Monique van der Vleuten, Gerard J. A. Rouwendal, Miranda M. C. Van der Lee, Benno Ingelse, Patrick H. Beusker, Wim H. A. Dokter
-
- 3180 3180 ATL-024, a novel topoisomerase I-based ADC targeting the tumor-specific glycopepitope CA242 (CanAg), demonstrates potent activity in colorectal and pancreatic cancer models, and excellent safety profile Warren Viricel, Edouard Leroy
- 3181 3181 Mutant p53-specific TAZ/TEAD pathway dependency as a therapeutic opportunity for triple-negative breast cancer Lydia Sakala, Yining Zhang, Jin G. Park, Joshua LaBaer
- 3182 3182 The FLT3 inhibitor quizartinib suppresses the WT1-driven activation of the KIT-STAT5-PIM signaling pathway and induces apoptosis in FLT3-wild type HL-60 cells Hideaki Yamauchi, Naoko Hosono, Takahiro Yamauchi
-
-
- 3185 3185 SCR-A019, a first-in-class biparatopic ADC targeting MSLN, with a novel topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models Qiong Wang, Yayuan Fu, Qi Deng, Chunlei Xia, Hui Zheng, Youfu Chu, Renhong Tang
- 3186 3186 MDM2 Knockdown Enhances Phosphorylation of MCM2 during Cell Cycle Progression Nikita Meghani, Viola Ellison, Jill Bargonetti
- 3187 3187 A patient-derived organoid screening platform for evaluating KRAS inhibitor efficacy Merel Derksen, Yasmine Abouleila, Mariana Martins Costa Silva, Gerben ten Hag, Rene Overmeer, Farzin Pourfarzad, Fabian Stavenuiter, Robert G. J. Vries, Sylvia F. Boj
